BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Claudio Chiappetta joins Chervon as Vice President of Retail Sales for Chervon Canada; effective Monday, October 5, 2026, reporting to VP, MD Neil Harrison. A graduate of York University in Toronto, Chiappetta majored in business and marketing. He brings over 25 years of outdoor power equipment and power tool experience to Chervon as well as extensive knowledge of the Canadian home improvement and outdoor power equipment markets. Chiappetta launched his tool and outdoor career in 2003 at Black & Decker/DeWalt where he held various sales and marketing positions including cordless product manager for DeWalt Power Tools. Claudio joined TTI Milwaukee in 2008 where he was responsible for the launch of a series of Milwaukee cordless products into the Canadian market. He went on to build and manage the Ryobi outdoor power equipment portfolio along with multiple TTI power tool brands. "I am delighted to welcome Claudio to our Canadian senior
Chervon Names Daniel L. Abbott Director of Sales - Western U.S.A.5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Daniel L. Abbott joins Chervon as Director of Sales - Western U.S.A.; effective Monday, October 5, 2026, reporting to SVP Matt DeFeo. Abbott brings over 30 years of experience in the power tool, outdoor power equipment, and home improvement industry. As a graduate of Long Beach State, Abbott went on to serve for 4 years in the United States Airforce. Abbott then moved on to become a Home Depot Store Manager in Huntington Beach, California. Abbott then joined TTI/Milwaukee where he spent 24 years building, managing and leading an elite west coast-based sales team. Abbott was promoted through increasingly responsible positions until his final role as sales leader of over 700 salespeople. "Abbott is a proven and exceptional leader and mentor of high-potential sales talent," says SVP Matt DeFeo. "His obsessive focus on teaming up with key accounts at the store level has unleashed years of extraordinary growth in his areas of responsibili
Securitas Technology Releases 2027 Global Technology Outlook Report5.10.2026 14:00:00 CEST | Press release
UNIONTOWN, OH / ACCESS Newswire / October 5, 2026 / Securitas Technology, one of the world's largest electronic security companies, today announced the release of its 2027 Global Technology Outlook Report, offering organizations practical insights into the technologies, trends, and business priorities transforming the electronic security industry. Highly anticipated by security professionals across the globe - and now in its ninth annual edition - the Global Technology Outlook Report brings together perspectives from more than 16,000 end-user clients across 19 countries, independent research with more than 575 security decision-makers, 26 of the world's leading manufacturers, innovators, and Securitas Technology subject matter experts from around the world. The result is the industry's most comprehensive view of how security programs are evolving to address growing complexity, emerging risks, and rapidly changing technology. As security increasingly supports business resilience, operat
Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Peter J. Carlson joins Chervon as Director of Sales for Strategic Accounts effective Monday, October 5, 2026, reporting to SVP of Industrial and Commercial Sales, Jeff Campbell. Carlson brings over 27 years of power tool and outdoor product key account management experience to Chervon. A graduate of Bemidji State University in Bemidji, Minnesota; Carlson launched his career at Makita Power Tools in 1999. He progressed through a series of positions at Makita over the subsequent 10 years. In 2009, Carlson joined TTI/Milwaukee as a Senior National Account Manager. His career flourished as he was promoted through a series of increasingly responsible positions building and managing strategic key account business for TTI/Milwaukee. "Carlson is highly regarded in his ability to not only build the business but also to mentor, train and develop his people," SVP Campbell said. "His extensive experience at building store level and E-Commerce gr
Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Neil Harrison joins Chervon as Vice President Sales, Marketing and Managing Director for Chervon Canada; effective Monday, October 5, 2026, reporting to CEO Joe Galli. Harrison brings more than 23 years of professional and consumer power tools experience. After studying environmental research management and graduating of the University of Western Ontario in London, Ontario; Harrison began his tool career in 2003 with Black & Decker/DeWalt, advancing through various positions in sales, operations, and product management. In 2006, Harrison joined Bosch Canada as marketing manager for the SKIL brand. He then went on to a position as an account manager with Hilti Canada. In 2008, Harrison joined TTI/Milwaukee, where he launched an impressive 17-year career advancing through leadership positions in product management, channel management, and marketing management. He went on to lead regional sales teams in the industrial construction chann
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom